Consistent benefit survival with cabazitaxel (CBZ) in metastatic castration resistant prostate cancer (mCRPC) in Spain: Updated results.
Iria González, Daniel Castellano, Emilio Esteban, Quionia Pérez Arnillas et autres
es (code pays fourni par la source)